Instructions for CME/NCPD: Complete the pre-test, listen to the
audio and view the slides, complete the post test, complete the
evaluation form and hit submit. You will be asked to enter your name
and email address on the pre-test, evaluation and post-test. If you
close your internet browser without completing the post test, you
will have ONE more opportunity to complete. A score of 70% must be
achieved on the post test to receive continuing education credits.
If you do not pass the post test after two attempts, you will not be
eligible to try again. Once you complete the evaluation form and
score 70% or higher on your post test, you will automatically be
given your certificate.
To print or save your certificate, you will need to click on the
“download” button and either print or save.
This activity is intended for healthcare professionals practicing in
managed care environments.
This activity is supported by
an educational grant from
Merck Sharp & Dohme Corp. and AstraZeneca.
Breast Cancer is the most common cancer found in women, regardless
of race or ethnicity. According to the American Cancer Society, an
estimated 281,550 new cases of invasive breast cancer are to be
diagnosed in women in the United States during 2020. The incidence
in women in the United States is 1 in 8 (about 12 percent). About
46,600 women are expected to die from breast cancer this year,
though death rates have been steadily decreasing over the past 20
years due to new and ever improving treatment options. However, in
the later stages of disease, when distant metastases are present,
cure becomes less likely and few patients are rendered free of
disease. Therapy in the advanced, metastatic setting then focuses on
prolonging life and managing disease-and treatment-related adverse
events. There is no single treatment strategy that will work for all
patients with metastatic breast cancer (MBC). Instead, treatment
selection must be individualized based upon patient- and
tumor-specific factors, as well as safety and efficacy profile of
available agents, with an emphasis on the combined goals of tumor
control, prolonged survival, and maintenance of patient quality of
life. Fortunately for patients with advanced breast cancer, several
new agents, including PARP inhibitors, have recently become
available. They have shown the ability to improve safety and
efficacy outcomes. With these options becoming available for the
treatment of metastatic breast cancer, it is critical to provide
medical directors, oncologists, practicing physicians and others on
the interprofessional management team with updated clinical data and
strategies on the changing treatment paradigm, with the ultimate
goal of improving patient outcomes
Upon completion of this
activity, participants will be able to:
Assess the clinical and economic
burden of metastatic breast cancer, including factors that
contribute to poor prognosis and increased costs
Examine the main signaling pathways
and key mechanisms in DNA damage repair and how deficiencies in
these pathways can lead to tumor proliferation and growth
Compare and contrast efficacy and
safety profiles and recent clinical data of current and emerging
targeted therapies, including PARP inhibitors, for the treatment
of advanced breast cancer
Identify patients based on molecular
changes and previous therapy that are most likely to benefit
from treatments with PARP inhibitors
Analyze evolving data regarding the
adverse event profiles of PARP inhibitors currently approved for
patients with breast cancers
Apply methods to enable optimal cost
management of PARP inhibitors to be realized by multiple
metastatic breast cancer stakeholders including managed care
||Filipa Lynce, MD
Breast Medical Oncologist
Dana Farber Cancer Institute
has served as a consultant for Pfizer, AstraZeneca, and
BMS. Dr. Lynce has received research funding from Pfizer
and BMS. Dr. Lynce has served as a speaker for ASCO
Advantage, Onclive Breast Meeting, ION National Meeting,
and PRIME. This presentation has been peer reviewed for
MD has no financial relationships with ineligible
companies to disclose.
Jeremy Williams has no financial relationships with
ineligible companies to disclose.
Jacqueline Cole, RN, MS, CMCN has no financial
relationships with ineligible companies to disclose.
NAMCP and/or the presenter
has copyright or has received permissions for use of
materials provided in this activity.
Accreditation & Designation
This activity has been planned and implemented in accordance with
the accreditation requirements and policies of the Accreditation
Council for Continuing Medical Education (ACCME) through the joint
providership of the National Association of Managed Care Physicians
(NAMCP) and American Association of Managed Care Nurses (AAMCN). The
National Association of Managed Care Physicians is accredited by the
ACCME to provide continuing medical education for physicians.
NAMCP designates this enduring material for a maximum of 1 AMA
PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their
participation in the activity.
The American Association of Managed Care Nurses is accredited as a
provider of nursing continuing professional development by the
American Nurses Credentialing Center's Commission on Accreditation.
Nurses who complete this activity and achieve a passing score will
receive 1 hour in nursing continuing professional development.
This activity has been approved by the American Board of Managed
Care Nursing for 1.0 contact hours toward CMCN recertification
This activity is supported by an educational grant from
Merck Sharp & Dohme Corp. and AstraZeneca.
NAMCP and/or this website does not
provide medical advice, diagnosis or treatment. NAMCP does not
endorse or imply endorsement of the content on any linked website.
This website is to be used as an informational resource. With any
health related concern, consult with your physician or healthcare
Click Here To Continue